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Abstract 
Oncolytic virotherapy is using oncolytic viruses (OVs) which selectively infect and kill cancer cells. Oncolytic 
viruses represent a highly targeted approach to established cancer that brings a multimechanistics approach and an 
acceptable safety profile to patients with a variety of cancers. A variety number of viruses have been developed as 
oncolytic virotherapeutics, including Adenovirus, Vaccinia virus, Herpesvirus, Measles, Coxsackie A virus, 
Newcastle disease virus, and Reovirus. Anticancer viruses can now be engineered to selectively attack cancer cells, 
spare normal tissue, awaken the host immune system and reverse immunosuppression in the tumor 
microenvironment. But virotherapy is not a cure on its own. Research suggests that virotherapies will serve to 
supplement chemotherapy, radiation therapy or immunotherapy. Combinations of OV with cytotoxic agents are 
feasible and safe, with the potential of transient immune supperssion of the host in order to increase viral access 
to the tumor and provide time for viral oncolysis to exceed the tumor’s replicative  potential. Granulocyte 
macrophage colony stimulating factor as an immune-stimulatory cytokine boosts host immune activity through 
the infiltration of dendritic cells and CD4+ and CD8+ T cells at tumor sites. Concomitants to human, cancer is the 
leading cause of death in companion animals such as dogs and cats. The most important challenges for the 
successful clinical use of OVs in veterinary practice are reduction of viral toxicity, optimization of virus delivery 
to tumor, and enhancement of viral spread throughout the tumor mass. The multifactorial, interplay can be 
determined by the complex interactions between the tumor and its microenvironment, the virus, and the host 
immune response. Yet, there is promise that OVs will soon be a new, powerful treatment option for veterinary 
patients with cancer. Hence, sound understanding of the biology of OVs and its application in veterinary medicine 
require.  
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1. INTRODUCTION 
The potential of viruses as anti-cancer agents was first realised in the early twentieth century, although coordinated 
research efforts did not begin until the 1960s (Alemany, 2013). Oncolytic virotherapy is an emerging anti-cancer 
treatment modality that uses OVs. One of the most attractive features of the OVs is that they are either naturally 
occurring or genetically engineered to selectively infect, replicate in and damage tumor cells while leaving normal 
cells intact (Workenhe and Mossman, 2014; Guo et al., 2008). In the 1920s animal experiments confirmed that 
viruses were capable of infecting and lysing experimental murine tumors and several studies followed in the 1950s 
demonstrating potent oncolysis of murine tumors by Newcastle disease virus and Influenza virus (Kelly and 
Russell, 2007). 
A mouse was considered the first animal model to demonstrate full regression through viral oncolysis 
(Nicholas et al., 2003). Incidence of cancer ranges from 1 to 2 percent in the canine population and currently 
accounts for about half of the deaths in dogs older than 10 years (Merlo et al., 2008). A number of viruses including 
adenovirus, reovirus, measles, herpes simplex virus, Newcastle disease virus, and vaccinia have been clinically 
tested as oncolytic agents (Donnelly et al., 2012). Most current OVs are engineered for tumour selectivity, although 
there are naturally occurring examples such as reovirus and the senecavirus (Roberts, 2006).  
Cancer is one of the most common causes of natural death in dogs in both developed and developing countries. 
It is among the top deadly diseases in dogs and cats (Merlo et al., 2008). In contrast to the progress of human 
oncolytic virotherapy, there are very few clinical trials using OVs for canine or feline cancer patients (Patil et al., 
2012). The most common forms of cancer in dogs and cats are skin, lymphoma, mammary, bone, connective tissue, 
and oral cancers (Paoloni and Khanna, 2008; Tang et al., 2010). Oncogenic viruses can establish a chronic infection 
allowing them to escape from the host’s immune-system while producing proteins that control cell death and 
proliferation. Chronic infection also leads to inflammatory reactions promoting cancer development (McLaughlin-
Drubin and Munger, 2008).  
To potentiate their immunogenic effects, genetic engineering strategies have been used to encode OVs with 
various cytokines, immunomodulators, and tumor associated antigens (Melcher et al., 2011). Clinical evaluation 
of adoptive T cell transfer and OVs are currently underway as mono- therapies (Patel and Kratzke, 2013). Viral 
oncolysis directly destroys tumor cells through either their lytic replication cycle or the expression of endogenous 
cytotoxic gene products (Chu et al., 2004). To further enhance their oncolytic effects, transgenes encoding pro-
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apoptotic proteins are inserted into OVs to subvert cell death machinery. These proteins include various death 
inducing ligands such as TNF-related apoptosis inducing ligand (Wohlfahrt et al., 2007; Zhao et al., 2006).  
Through transgene insertion, OVs can serve as directed gene delivery vehicles, and thus accommodate a 
diverse array of therapeutic strategies. Arming OVs with additional weaponry, such as pro-apoptotic genes, tumor 
suppressors, or genes stimulating antitumor immunity, can enhance their killing capacity. With a broad arsenal, 
modified OVs have the potential to target a wide spectrum of different cancer types. Moreover, administration of 
OVs as a monotherapy has demonstrated varying degrees of success in clinical trials (Vacchelli et al., 2013; 
Buonaguro et al., 2012). 
Over an extended period, selective pressure on heterogeneous tumor populations can also lead to therapeutic 
resistance to OVs via receptor loss or mutation of essential signaling pathways required for viral replication 
(Moerdyk-Schauwecker et al., 2013). NDv binds cells via the hema gglutinin neuraminidase (HN) protein (Park 
et al., 2003). PV701 and MTH68/H are live attenuated oncolytic viral strains of NDv, which have the capacity to 
selectively replicate in and lyse tumor cells and to cause immune-stimulation (Fournier et al., 2012) and become 
one of the promising new therapeutic approach of oncolytic virotherapy. OVs exhibit selective viral replication in 
tumors and metastases resulting in the killing of cancer cells and the initiation of tumor-specific immunity (Liu et 
al., 2007; Chen and Szalay, 2011).  
Canine cancers share many features in common with human cancers including histological appearance, tumor 
genetics, molecular targets and response to conventional therapy (Al-Dissi et al., 2010; Mederle et al., 2010; 
Amorim et al., 2010). In both species, tumor initiation and progression is influenced by similar factors like age, 
nutrition, sex and environmental exposure (Hlavaty et al., 2011). One reason for the lack of efficient therapeutic 
response associated with early conditionally replicative adenoviruses can be the absence of the primary canine 
adenovirus receptor (CAR) on some cancer cells, as has been reported in gastrointestinal, pancreatic, ovarian, and 
hormone refractory prostate cancers. Specific strategies to enhance CAR-independent transduction of 
conditionally replicative adenovirus refractory cancer cell types and improve tumor-specific immunity have 
utilized modifications to the viral coat to induce better cancer selectivity and provide proinflammatory signals. 
Adenovirus-35 is a strain that utilizes CD46, rather than CAR, as the primary receptor for initial adsorption and 
entry (Gaggar et al., 2005; Sirena et al., 2004). This vector demonstrated enhanced selectivity and stronger 
adenovirus affinity for the targeted cell (Tanaka et al., 2006). Moreover, control mechanisms have been added to 
adenoviruses to ensure cancer cell specificity, and arming the virus with suicide genes has also been explored to 
improve therapeutic effects (Liu et al., 2005). Adenoviruses are also being tested as therapeutic agents for canine 
cancers. Human adenovirus 5 has been shown to productively replicate in canine osteosarcoma and canine 
mammary carcinoma cells (Ternovoi et al., 2005). 
Herpes simplex virus tumor selectivity is enhanced further by gain of function mutations occurring in given 
oncogenes of the Ras-signaling pathway of transformed cells, whereby tumor cells with augmented Ras activation 
are significantly more susceptible to oncolytic herpes simplex virus infection than healthy cells with normal Ras 
signal transduction pathway physic- ology (Pan et al., 2009). Recruitment of innate immune cells associated with 
direct lysis of tumor cells and priming of adaptive immunity was seen, including an accumulation of activated 
natural killer cells and immunogenic dendritic cells (Benencia et al., 2005). 
Coxsackie virus could also activate neutrophils to release interferon-β and antigen-presenting cel ls and to 
induce cytotoxic T lymphocytes (Jablonska et al., 2010). Coxsackie virus B3 exhibit ed potent tumor cell lysis in 
a number of non-small cell lung cancer cell lines, even in cancer cells refractory to conventional radiotherapy and 
molecular targeted therapies (Prestwich et al., 2009). OVs induces oncolytic-mediated tumor regression, insertion 
of the gene encoding GM-CSF resulted in rejection of distant noninjected A20 tumors in mice, suggesting the 
vector could induce potent local oncolytic effects and generate systemic antitumor immunity (Liu et al., 2003). 
Reovirus oncolysis of cancer cells is mediated mainly via the extrinsic apoptosis pathway (Clarke et al., 2007; 
Smakman et al., 2006). Depending on the tumor cell infected, reovirus induced apoptosis uses different 
proapoptotic molecules to activate apoptosis. For example, the HeLa cell line requires NF-κB for apoptosis, while 
specific ovarian, breast, and lung cancer cell lines activate death receptor pathway of apoptosis (Clarke et al., 
2007). 
Reovirus, like other oncolytic vectors, is subject to immune recognition and rapid clearance. Use of immune 
suppressant drugs, such as cyclophosphamide and cyclosporine A, has been shown to potentiate oncolysis and 
increase reovirus replication in injected tumor tissue with enhanced reovirus-mediated tumor clearance (Qiao et 
al., 2008). An oncolytic measles virus armed with genes coding for antibodies against inhibitory immune 
checkpoints has been shown to have improved antitumor activity compared to control virus. It appears to be a 
synergistic effect between oncolytic measles virus and immune checkpoint inhibitors (Engeland et al., 2014). 
Although, a lot of studies have been done over the causes of cancer, there is still the paucity of information 
regarding to virotherapheutic efficacy and associated factors in animal cancer. Therefore, the objectives of this 
review are: 
 To give the base line overview on oncolytic virotheraphy for cancer cells. 
Advances in Life Science and Technology                                                                                                 www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) 
Vol.79, 2020 
 
29 
 To describe the major OVs utilized with various tumor cells. 
 To describe the mode of actions, advantages and limitations of some of the viral vectors 
commonly used for oncolytic virotherpy incompnien animals.  
 
2. ONCOLYTIC VIROTHERAPY FOR CANCER CELLS IN VETERINARY MEDICINE 
An OVs is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by 
oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour (Ferguson et 
al., 2012; Casjens, 2010). OVs are thought not only to cause direct destruction of the tumour cells, but also to 
stimulate host anti tumour immune system responses (Melcher et al., 2011; Lichty, 2014). Adenovirus 5 (Ad5) 
subtype has been extensively used in oncolytic virotherapy as a vector (Ginsberg, 2013). 
Herpes simplex virus (HSV) was one of the first viruses to be adapted to attack cancer cells selectively, 
because it was well understood, easy to manipulate and relatively harmless in its natural state (merely causing cold 
sores) so likely to pose fewer risks. The herpes simplex virus type 1 (HSV-1) mutant 1716 lacks both copies of the 
ICP34.5 gene, and as a result is no longer able to replicate in terminally differentiated and non-dividing cells but 
will infect and cause lysis very efficiently in cancer cells, and this has proved to be an effective tumour targeting 
strategy(van den Hengel et al., 2013). In a wide range of in vivo cancer models, the HSV1716 virus has induced 
tumour regression and increased survival times (Allen et al., 2013; Josupeit et al., 2016). 
The current trend is to use recombinant strains with decreased pathogenicity and improved antitumor effect. 
However, naturally occurring oncolytic NDV strains are also observed. The oncolytic potential of NDV strains 
circulating in wild migratory birds of Russia remains poorly understood. The oncolytic wild-type NDVs from 
natural reservoirs obtained in 2008–2014 in Russia. They are demonstrate the in vitro ability of NDVs to influence 
the viability of tumor cells after infection and evaluate in vivo efficiency of NDV strain against non-small cell 
lung carcinoma (li et al., 2011, Song et al., 2010, Bai et al., 2014, Elankumaran et al., 2010, Zamarin et al., 2009 
and An et al., 2016). 
Canine lymphoid cell lines and B and T lymphocytes established from dogs with lymphoma have been shown 
to express CD150 receptors. Attenuated CDV has been tested for oncolytic property in the lymphoma cells and 
was able to infect and induce apoptosis in these cells (Suter et al., 2005). The molecular mechanisms underlying 
virus induced carcinogenesis are diverse and complex. In addition to causing direct effects such as induction of 
genomic instability, DNA damage, and viral oncogene triggered cell transformation (Chen et al., 2014). 
 
2.1 Mechanisms of Oncolytic Virus-mediated Tumor Ablation 
2.1.1 Tumor tropism and oncolysis 
Oncolytic virotheraphy have the ability to establish a niche of continuous viral replication within the tumor, recruit 
uninfected cells in proximity creating syncytia, infect dividing and non-dividing cells, and be stable in vivo, yet 
lack chromosomal integration and do not result in major disease (Verheije and Rottier, 2012).  OVs, like reovirus 
(Prestwich et al., 2012), vaccinia virus (Thorne et al., 2008), can induce tumor specific adaptive immune responses 
and indirectly cause malignant cell death. Adenovirus (Diaconu etal., 2012),Coxsackie B3(Miyamoto et al., 
2012)and measles virus (Donnelly  et al., 2013),  can lead to endoplasmic reticulum stress and cause immunologic 
cell death a type of cell death that leads to release of danger association molecular patterns, like adenosine 
triphosphate, calreticulin and high mobility group box-1, which attract immune cells (Kepp  et al., 2011). 
OVs can also selectively target tumor neovasculature. Vesicular stomatitis virus (VSV) can selectively infect 
endothelial cells in the tumor microenvironment and cause thrombosis in the tumor vessels (Breitbach et al., 2011). 
HSV and vaccinia virus can also selectively damage tumor endothelium(Benencia et al., 2005; Breitbach et al., 
2013); preferential replication in tumor vessels may be secondary to the dependence on high vascular endothelial 
growth factor (VEGF) and fibroblast growth factor (FGF) levels for replication in normal endothelium (Breitbach 
et al., 2013) . 
Therefore, instead of relying on receptor specificity, tumor tropism of vesicular stomatitis virus is dependent 
on the permissiveness of malignant cells to viral infection. VSV belongs to a class of interferon (IFN) sensitive 
viruses, which preferentially infects tissues exhibiting reduced or absent IFN responsiveness (Krishnamurthy et 
al., 2006; Stojdl et al., 2003; Noser et al., 2007). Selective retargeting of viruses to tumor cells can also be 
generated in viruses without innate oncolytic abilities. Adenovirus based vectors are a good demonstration of this 
approach, since they possess a wide tropism, but a lytic life cycle that can be exploited for oncolytic virotherapy 
(Kruyt and Curiel, 2002).The pathogenicity and tissue tropism are similar within the subgroups (Wold and Toth, 
2013).  
Viruses are small passive particles that reach their target cells via either radial cell-to-cell spread or diffusion 
across concentration gradients in soluble matters, such as blood, and propagate infection. They are higher the 
number of infectious virions at the tumor territory, the higher the probability of infecting and destroying every 
single tumor cell (Miller and Russell, 2014; Smith et al., 2014). It is important to investigate how infection of the 
host normal cells by the OVs can enhance the oncolytic virotherapy. To normal cells, such as liver, that can be 
Advances in Life Science and Technology                                                                                                 www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) 
Vol.79, 2020 
 
30 
quickly self regenerated after a trauma or disease, infection of normal cells could be tolerable if such infection is 
not endemic (that means the infection does not persist forever) and could potentially aid to control tumor growth 
(Ribacka and Hemminki, 2008). 
Measels virus (MV) enters cells through interaction of its H-protein and cellular CD46 (membrane cofactor 
protein) and signaling lymphocyte activating molecule (Tatsuo et al., 2000). CD46 is overexpressed on tumor cells 
(Fishelson et al., 2003), MV vaccine affects only cells with a high density of CD46, and therefore, does not affect 
normal cells (Anderson et al., 2004). MV kills tumor cells by inducing cell-to-cell fusion through F-protein, 
formation of syncytia and subsequent apoptotic death (Anderson et al., 2004). Several preclinical studies in animal 
models, including both solid tumors and hematologic malignancies, have evaluated MV through different routes 
(ITu, IV, IP or intrapleural) and administration schedules (Blechacz et al., 2006).  
The enzymes thymidine kinase and ribonucleotide reductase in cells are responsible for DNA synthesis and 
are only expressed in cells which are actively replicating (Gentry, 1992). These enzymes also exist in the genomes 
of certain viruses like HSV, vaccinia and allow viral replication inquiescent (non-replicating) cells (Singh et al., 
2012), so if they are inactivated by mutation the virus will only be able to replicate in proliferating cells, such as 
cancer cells. All these models were used to investigate adenoviral targeting on cancer stem-like cells. Resistant 
cancer stem-like cells constitute a major hurdle in cancer therapy, especially when combating glioblastomas. As 
such, reovirus, measles vaccine virus, and parvovirus have been successfully targeted to glioblastoma stem-like 
cells in spheroid models (van den Hengel et al., 2013, Josupeit et al., 2016). Treated animal tumors demonstrate 
cytopathic effect with syncytia formation followed by apopt- otic cell death of MV-infected tumor cells (Zhang et 
al., 2012). Canine p53 family proteins have biological activities similar to their human counterparts (Zhang et al., 
2009), mutations in conserved domains of p53 appear to play a significant role in mammary carcinogenesis in both 
humans and dogs (Queiroga et al., 2011). 
Oncolytic viruses are distinguished by their property to either inherently or after genetic modifi -cation 
replicates selectively in cancer cells. These viruses have multiple mechanisms to harm the host cells including 
direct lysis, induction of apoptosis and autophagy, expression of toxic prot- eins and shutdown of proteinsynthesis. 
At the end of the replication cycle, cells are destroyed and infective viral progeny is released into remaining tumor 
tissue. In addition to local amplifying antitumor effect, infective viral particles are able to enter the systemic 
circulation and infect distant metastasis (Roberts et al., 2006). 
2.1.2 Induction of antitumor immune responses 
To enhance viral distribution and tumor cell killing, irradiation has been successfully combined with an oncolytic 
adenovirus in glioblastoma spheroids (Lamfers et al., 2007). Lower myxoma-virus-mediated cell killing in 
spheroids than in adherent cells, because of downregulated Akt kinase in non-adherent cells (Correa et al., 2012). 
An oncolytic virus destroys tumors either by direct viral lysis of tumor cells(Atherton andLichty, 2013; Gentschev 
et al., 2012), by the destruction of the tumor vasculature (Gentschev et al., 2012), by induction of host antitumoral 
immune responses(Gentschev et al., 2013; Fridlender et al., 2009) or most likely, a combination of these 
mechanisms(Moehler et al., 2005)(Figure 1). An increased infiltration of neutrophils, macrophages and natural 
killer cells to the tumor site might be involved in the vaccinia virus mediated immune response in different canine 
cancer xenograft models (Breitbach et al., 2007; Winkler et al., 2004). 
The presence of such activated inflammatory cells in the tumor tissue may enhance the antitumoral effect by 
increasing the phagocytic or cytotoxic activities of these cells (Ferrara et al., 2003; Millanta et al., 2002). In 
addition, an increase in proinflammatory interferon gamma (IFN-gamma), interleukin-2 (IL-2), interleukin-6 (IL-
6), tumor necrosis factoralpha (TNF-alpha), interferon gamma-induced protein 10 (IP-10), macrophage 
inflammatory protein-1 alpha (MIP-1 alpha), macrophage inflammatory protein-1 beta (MIP-1 beta), monocyte 
chemotactic protein-1 (MCP-1), and monocyte chemotactic protein-3 (MCP-3) was observed in vaccinia 
virusinfected canine xenografted mice(Patil et al., 2012). 
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Figure 1: Possible mechanisms of oncolytic virus-mediated tumor ablation. 
Many of these proteins stimulate innate immunity mediated by dendritic cells, neutrophils, macrophages and 
NK cells. OVs naturally prevent neoangiogenesis either by direct infection and destruction of tumor vasculature 
(Adelfinger et al., 2014) or “vascular normalization” in tumor tissue, as described by Winker and colleagues 
(Breitbach et al., 2016). IFNs are a group of secreted cytokines; exert pleiotropic effects on important cell 
functions, including cell prolifera tion and modulation of the immune system (Dunn et al., 2006; Stetson and 
Medzhitov, 2006).  
 
2.2 Use of Oncolytic Virotherapy of Cancer in Animals 
2.2.1 Toxicity of Oncolytic Viruses to Pet Cancer Patients 
Some NDV strains have been developed to elicit potent oncolytic capacity.The MTH-68/H strain showed 
beneficial effects in patients with advanced cancer (Csatary et al., 2004).This strain exerts direct cytotoxicity in 
vitro against various tumor cell lines, suggesting that direct cytotoxicity and oncolysis are key factors in the 
antitumor activity. NDV-induced apoptosis of infected tumor cells is the dominant mode of cytotoxicity, but 
activation of either the intrinsic or extrinsic apoptotic pathways is cell type dependent (Elankumaran et al., 2006). 
Overall, onco lytic virus therapy has been well tolerated, with largely minor and expected toxicity, and no evidence 
of uncontrolled or latent infection, household transmission, or malignant transfor   mation (Russell et al., 2012; 
Cattaneo et al., 2008). 
Table 1: Oncolytic viruses tested for cancer therapy.  
Virus strain 
Virus 
family/Virus type 
Study/Tumor type/Animal model Ref. 
Canine adenovirus type 2 
(CAV2) 
Adenoviridae 
(double stranded 
DNA viruses) 
Infection of canine osteosarcoma 
cells and osteosarcoma xenografted 
mice 
(Hemminki et al., 2003) 
Human adenovirus type 5 
(Ad5) 
Adenoviridae 
Infection of canine osteosarcoma, 
melanoma and mammary carcinoma 
cells 
(Ternovoi et al.,2005) 
Ad5, CAV2 Adenoviridae 
Infection of canine cells and 
osteosarcoma xenografted mice 
(Le et al., 2006) 
CAV2 Adenoviridae 
Infection of canine osteosarcoma 
cells and healthy dogs 
(Smith  et al., 2006) 
CAV2 Adenoviridae 
Treatment of canine osteosarcoma 
xenografts using tumor cells as a 
carrier for CAV2 
(Alcayaga-Miranda  et 
al., 2010) 
Ad5-based vector with CD40 
ligand (AdCD40L) 
Adenoviridae 
Treatment of canine malignant 
melanoma patients 
(Westberg et al., 2013; 
Suter et al., 2005) 
Ad5-based vector encoding 
IL-12 (Ad hsp feline IL-12) 
Adenoviridae 
Treatment of cats with soft tissue 
sarcoma 
(Siddiqui  et al., 2007) 
Ad5-vector-mediated p53 
gene transfer 
Adenoviridae 
Treatment of canine osteosarcoma 
xenografts 
(Kanaya  et al., 2011) 
Canine Distemper Virus Paramyxoviridae Infection of canine lymphoid, (Suter et al., 2005) 
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Virus strain 
Virus 
family/Virus type 
Study/Tumor type/Animal model Ref. 
(CDV) (single stranded 
RNA viruses) 
osteosarcoma and melanoma cells  
Reovirus 
Reoviridae (double 
stranded RNA 
viruses) 
Infection of canine mast cell tumor 
cells (MCT) and treatment of MCT 
xenograft mice 
(Hwang  et al., 2013)  
Vaccinia virus (Lister) strain 
(GLV-1h68)  
Poxviridae (double 
stranded DNA 
viruses) 
Treatment of canine mammary 
adenoma and carcinoma and soft 
tissue sarcoma xenograft mice  
(Gentschev et al., 2009; 
2010; 2012) 
Vaccinia virus (Lister) strain 
expressing anti-VEGF 
antibody (GLV-1h109) 
Poxviridae 
Treatment of canine soft tissue 
sarcoma and prostate xenograft mice 
(Patil  et al., 2012) 
Vaccinia virus (Lister) strain 
(LIVP 6.1.1) 
Poxviridae 
Treatment of canine soft tissue 
sarcoma and prostate xenografted 
mice 
(Gentschev  et al., 
2013)  
Vaccinia virus (Lister) strain 
expressing anti-VEGF 
antibody (GLV-5b451)  
Poxviridae 
Treatment of feline mammary 
carcinoma xenograft mice 
(Adelfinger  et al., 
2014)  
Myxoma virus (MYXV) Poxviridae 
Infection of different canine tumor 
cells 
(Urbasicet al., 2012) 
Myxoma virus (MYXV) Poxviridae Infection of feline carcinoma cells (MacNeill et al., 2012)  
Canary pox virus expressing 
IL2 (ALVAC-fIL2)  
Poxviridae 
Therapy of cats with feline 
fibrosarcomas  
(Jourdier  et al., 2003)  
Vaccinia virus (Copenhagen) 
strain expressing IL2 
(NYVAC-fIL2) 
Poxviridae 
Therapy of feline fibrosarcoma 
patients 
(Jourdier  et al., 2003) 
2.2.2 Optimization of Onclytic virotheraphy delivery to the Tumor tissue and metastases 
As a result, oncolytic virotherapy may result in incomplete eradication of the primary tumor mass or possibly even 
promote metastasis of the tumor cells and eventually leading to recurrence of disease. Similar to what is observed 
in chemotherapy and radiotherapy regimens, malignant cells are also prone to become resistant to oncolytic 
virotherapy over time. This is presumably linked to the intrinsic nature of cancers to exhibit genomic instability 
and the propensity for accumulating mutations (Alain et al., 2006; Vitale et al., 2011). 
Viral replication was demonstrated via transgene expression of GFP or luciferase. Moreover, they quantified 
viral DNA in the supernatant. In conclusion, the authors showed replication of the wild-type adenovirus in liver 
slices, whereas replication of the tumor targeted virus was almost fully restricted to tumor slices and attenuated in 
liver slices. Mixed slices are containing tumor and healthy liver tissue (Zimmermann et al., 2009). Genetic 
engineering of oncolytic viruses is supported by the safety data from genetically engineered products like DNA 
vaccine in dogs and non-human primates (Peruzzi et al., 2010; Pluhar et al., 2010). 
Multiple ambiguities exist regarding the optimization of combination strategies. It is unclear when the OV 
should be administered in regards to other novel agents. For example, administration of checkpoint inhibitors with 
OV on the same day or subsequent days in clinical trials or preclinical models has been performed but not been 
compared in a single study. Real-time evidence of enhanced antitumor immune response generation as well as 
dynamic imaging for tumor perfusion may be methods that predict the benefit from oncolytic virotherapy. For 
example, in patients treated with T-VEC who develop minimal increase in CD8+ T cells from baseline after 6 
weeks of therapy, the risk of subsequent disease progression is high (Puzanov et al., 2016). 
Canine osteosarcoma cells treated with replication selective canine adenovirus (OCCAV) were used as virus 
carriers for evading pre-existing neutralizing antibodies against adenovirus. When administered systemically, even 
in the presence of adenovirus neutralizing antibodies, OCCAV carrier cells showed superior infection of tumors 
and tumor regression in a xenograft mouse model compared to OCCAV (osteosarcoma cell canine adenovirus) 
alone (Alcayaga-Miranda et al., 2010). Moreover, the enhanced oncolytic effects were attributed to an increase in 
the effective local viral dose in the tumor as a con- sequence of the tumor specific delivery of the virus by the cells 
and the escape of the pre-exist- ing antiviral immunity (Power et al., 2007;  Fujiwara  et al., 2011). 
2.2.3 Enhancing anti-tumor immunity and/or anti-tumor effects of OVs by virus-integrated genes 
Oncolytic viruses (OVs) have a number of advantages over conventional antitumor agent, because they have their 
own cancer specificity and better safety margin. They selectively target and replicate in cancer cells, as a host cell; 
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thus, OVs survive by lysing cancer cells (Guo et al., 2008). OVs-mediated oncolysis not only leads to tumor 
regression but also provides important immune responses. Key signals provided by oncolysis to dendritic cells and 
other antigen-presenting cells (APCs) can then initiate additional potent antitumor immune response (Kaufman et 
al., 2015). OVs have been recently recognized as an effective treatment for cancer in preclinical models and 
promising clinical responses in human cancer patients (Russell et al., 2012). 
In addition to its oncolytic characteristics, OV can be engineered to express some functional genes. For 
instance, granulocyte macrophage colony-stimulating factor (GM-CSF) expression in OVs increases tumor cell 
lysis. GM-CSF is an immune modulator, acts as a paracrine manner on various cells, and recruits circulating 
neutrophils, monocytes, and lymphocytes to enhance their functions in host defense (Kanerva et al., 2013). As for 
HCC treatment in clinical trials, adeno- virus and vaccinia virus are mostly used (Downs-Canner et al., 2016; 
Samson et al., 2016). Oncolytic viruses form a diverse biological group whose members belong to at least 10 
different virus families, contain either an RNA or a DNA genome, and vary considerably as regards geno me size, 
particle complexity, and natural host preferences (Russel  et al., 2012).  
OVs naturally possess or are engineered to acquire the capacity to selectively infect, replicate in, and destroy 
tumor cells (oncolysis) while sparing their normal counterparts (Russel et al., 2012; Kelly and Russel, 2007). 
Multiple factors explain this onco-selectivity altered expression by tumor cells of virus entry receptors and/or 
intracellular permissiveness factors, rapid tumor cell division and high metabolic activity, deficient antiviral type 
I interferon responses in tumor cells (Lawler et al., 2016). Furthermore, there is mounting evidence that OV 
infection of tumor cells induces an immunogenic process, with neo-antigen recognition and establishment of 
specific antitumor immune responses (Lichty et al., 2014). 
Enhanced glioma cell killing has been observed when the virus was applied shortly after tumor cell irradiation, 
suggesting that this protocol might be translated to cases of non-resectable recurrent glioblastoma (Geletneky et 
al., 2010). In animal models, local, systemic, or intranasal administration of H-1PV has been found to cause 
regression of advanced tumors, virus replication being restricted to tumor tissues (Geletneky et al., 2010; 
Kiprianova et al., 2011). In addition, administration of this modified canine adenovirus to normal dogs showed 
only moderate virus-associated toxicity and showed therapeutic benefits in the xenograft model in killed canine 
osteosarcoma cells in cell culture (Carter et al., 2005). 
In addition, armed oncolytic viruses can also prevent neoangiogenesis, leading to cancer cell necrosis. 
Vascular endothelial growth factor (VEGF) is a protein that plays a key role in tumor angiogenesis (Hicklin and 
Ellis, 2005). Another approach that has been used to enhance viral potency has been to arm a conditionally 
replicative adenovirus with transgenes that promote anti tumor activity through other mechanisms, including use 
of antiangiogenesis and immuno stim ulatory genes (Jin et al., 2005; Seth et al., 2006). Evasion of the immune 
system has been accom plished by the use of chemical polymers or poly-ethylene glycol to coat conditionally 
replicative adeno viruses, which in turn increased local virus delivery to tumor sites (Doronin et al., 2009). 
Other approaches have tried to enhance the intrinsic cytolytic properties of NDV via increased expression of 
native viral proapoptotic proteins (example, F-protein), inhibition of innate immune responses for enhancement of 
viral replication and cell-to-cell spread, tumor-associated antigens, and immunostimulatory cytokines (example, 
GM-CSF, IL-2, and tumor necrosis factor-α) (Zamarin et al., 2012).The importance of the immune response with 
oncolytic NDV vectors has been highlighted in murine tumor models (Fournier et al., 2012). Therapeutic activity 
can be seen with only a small dose of injected NDV, suggesting that therapeutic responses are not comp letely 
dependent on the oncolytic activity of the virus (Bian et al., 2006). 
2.2.4 Successful combination therapy is context-dependent 
Recently, the combination of oncolytic virotherapy with chemotherapy has shown that use of these two therapies 
with very distinct antitumor mechanisms may also lead to synergistic interactions (Wennier et al., 2011). Oncolytic 
viruses as a standalone therapeutic intervention have rarely been shown to induce complete, long-term regression 
of established tumors in vivo (Vaha-Koskela et al., 2007). The use of recombinant OVs as clinical biotherapies, it 
is important to determine whether viremia could be induced that could result in shedding of the OV. The use of 
Ad 5 - prime/MG1-booster vaccination as a promising, novel therapy for testing in the context of veterinary clinical 
trials (Doronin et al., 2009;  Thorne et al., 2007). 
The efficiency of OV replication in tumor bearing immunocompetent dogs may be enhanced by various 
means such as combination of viro- with chemo-(MacTavish et al., 2010) or radiation therapy (Advani et al., 2011) 
or the conjunctive use of different oncolytic viruses (Le Boeuf et al., 2010). Recombinant vaccinia vectors 
encoding tumor associated antigens have demonstrated antitumor activity in murine tumor models (Kirn and 
Thorne, 2009; Thorne et al., 2005). A new generation of oncolytic vaccinia viruses co-expressing tumor antigens 
and a variety of proinflam matory cytokines has shown improved therapeutic responses and induction of tumor 
specific immunity in animal models and early-phase clinical studies (Liu et al., 2008; Park et al., 2008).  
Induction of antitumor immunity is likely aided by oncolytic-mediated cell death and release of tumor 
antigens and danger signals, such as ATP and high mobility group box-1, into the extracellular microenvironment 
(Guo et al., 2005). Viral-mediated oncolysis that induces release of these and other immunogenic signature mole 
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cules (example, calreticulin) during cell death can promote an antitumor immune response and be further enhanced 
by viral expression of immunomodulatory transgenes (eg, GM-CSF). The potential benefit of this approach was 
initially reported for a recombinant vaccinia virus encoding GM-CSF that abrogated formation of B16 melanoma 
tumors in mouse models (Thorne et al., 2007). A number of clinical trials have combined oncolytic viruses with a 
second form of therapy. These trials include widely used chemotherapeutics, such as cisplatin or radiation, and 
these trials have shown a high frequency of clinical responses (Russell et al, 2012). 
The effect of the combination of an oncolytic measle virus with the novel oral HDACi resminostat (Res) was 
checked in HCC cell panels. The combination effect showed a boosted cytotoxic effect as an enhanced induction 
of apoptosis with improved rate of primary infections (Ruf et al., 2015).The generation of an antitumor immune 
response is an indirect mechanism of malignant cell death for both OV infected and non-infected cells vasicular 
stomatitis virus (Pecora et al., 2002). Cyclophosphamide has been shown in preclinical animal models to improve 
reovirus access to the tumor and preserve neutralizing antibody levels sufficient for prevention of severe toxicity 
(Qiano et al., 2008). But, they did not appear to affect antibody levels and duration of viremia (Kolb et al., 2015). 
Gemcitabine appears to negatively impact late phases of reovirus replication; however, the net effect is 
synergistic as it accelerates antitumor immunity generation most likely by decreasing immune suppressive cells 
within the tumor microenvironment (Gujar et al., 2014). Antibody response to Reolysin also appears to be 
attenuated with this combination strategy (Lolkema et al., 2011). Activation of the programmed death-
1/programmed death-ligand 1 (PD-1/PD-L1) axis in tumor cells can be induced by oncolytic virotherapy 
(Mahalingam et al., 2015; Ranki et al., 2016), a finding likely related to natural stimulation of checkpoint 
molecules in the setting of chronic viral infections in order to minimize tissue damage (Keir et al., 2008). 
There are preclinical data for synergy between OVs and immune checkpoint inhibition. In melanoma 
xenografts, the combination of Reolysin and anti-PD1 antibody significantly prolonged mice survival compared 
to either agent alone (Rajani et al., 2016).There was evidence of enhanced antitumor cytotoxic T cell and natural 
killer (NK) cell activity with the combination therapy. Suppression of antitumor immunity by regulatory T cells 
(Treg) in Reolysin alone treated mice was ameliorated by anti-PD1 therapy. In an immunotherapy resistant lung 
adenocarcinoma animal model, treatment with oncolytic adenovirus plus anti-PD-1 antibody significantly 
increased antitumor immune responses to multiple neoantigens and decreased tumor growth, suggesting reversal 
of anti-PD-1 resistance with oncolytic virotherapy (Woller et al., 2015).  
NDV combined with immune checkpoint inhibition in immunogenic and non-immunogenic tumor animal 
models led to increased antitumor immunity and efficacy compared to either agent alone (Zamarin et al., 2014). 
Synergy of oncolytic VSV with anti-PD1 antibody therapy has been also demonstrated in glioma models (Cockle 
et al., 2016). Synergy of ITu vaccinia virus with ITu immune checkpoint blockade and radiation had been 
established in a lymphoma xenograft model, with tumor shrinkage in both treated and untreated tumors (Minev et 
al., 2014). The results of oncolytic virotherapy and immune checkpoint inhibition in a Phase I clinical trial are 
promising (Puzanov et al., 2015).  
2.2.5 Biosafety of Treatment 
The tumor normal immune viral dynamics 1–4 days in the presence of immune response triggered by the escalated 
viral infection of normal cells. This is very important because the induction of activated CD8+ T cells into the 
tumor site may limit subsequent oncolytic virus spread and intratumoral infection. It is important to note that the 
innate immune response against the virally infected cells is often active in about 2–7 days post-infection (Carolan 
et al., 2016). 
Non-replicating or replicating viruses can be used as a gene transfer vector to introduce for example a 
therapeutic gene, co-stimulatory molecule or cytokine into cancer cells or to prime lymphocytes with tumor 
antigens in cancer vaccine approaches (Roberts et al., 2006). There are two important aspects to oncolytic 
virotherapy; there is a direct treatment of tumors with replica ting oncolytic viral vectors alone or in combination 
with therapeutic transgene delivery, chemo therapy, or radiation therapy. On the other hand, there is indirect 
increase of antitumor immunity through a modulation of the immune response, as with viral oncolysate vaccine, 
and tumor protective monoclonal antibodies (Mathias et al., 1994). 
Treatment with JX-594 induced antitumor immunity, as evidenced by regression of distant uninjected lesions, 
and appearance of tumor infiltrating eosinophils, T cells, B cells, and macrophages in injected lesions. Further 
studies have suggested that the oncolytic activity and transgene expression of JX-594 are highly selective and 
mediated via several mechanisms, including activation of replication by epidermal growth factor receptor and Ras 
signaling, cellular thymidine kinase levels, and an abnormal interferon response in tumor cells (Parato et al., 2012). 
 
2.3 Limitations and Prospects of Cancer Gene Therapy 
The induction of activated CD8+ T cells into the tumor site may limit subsequent oncolytic virus spread and 
intratumoral infection. Even though they do not model the innate immune responses, it is important to note that 
the innate immune response against the virally infected cells is often active in about 2–7 days post-infection 
(Carolan et al., 2016). The role of GM-CSF in promoting proliferation of monocyte-derived suppressor cells 
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suggests that caution may be needed when using GM-CSF to enhance the immunostimulatory properties of 
vaccinia and other viruses (Filipazzi et al., 2007). Tumors can develop multiple barriers to various anticancer 
therapies, including oncolytic virotherapy. Several mechanisms that may hinder the therapeutic efficacy of OVs 
and the challenges they pose to the development of improved cancer virotherapies. 
2.3.1 Immunological barriers 
Immune responses against viruses presumably limit ongoing viral replication in immuno competent dogs. In this 
context, a high level of pre-existing immunity to parental viruses in canine populations might limit the use of 
oncolytic viruses for cancer therapy. The role of virus neutralizing antibodies following intravenous administration 
remains to be determined. Use of unrelated viruses from different hosts, such as vaccinia for dog cancers, may 
solve the problem of pre-existing immunity. However, carrier cell based therapy also provided promising results 
to escape pre-existing immunity (Fujiwara et al., 2011). 
Specific delivery to tumors and escape of the pre-existing antiviral immunity increased the effective local 
viral dose in the tumor tissue and thus enhanced the oncolytic effects (Hamada et al., 2007; Iankov et al., 2007). 
In order for an OV to establish a niche within the tumor after systemic administration, the OV has to by pass the 
liver that may actively sequester a percentage of the administered dose (Alemany et al., 2000). Administering the 
virus directly within the tumor overcomes this limitation, mainly in the minority of tumors with easily accessible 
skin and subcutaneous lesions such as melanoma, with an abscopal effect and dissemination in distant sites 
(Andtbacka et al., 2015; Senzer et al., 2009 and Zamarin et al., 2014). 
The adaptive immune system may be a double edge sword, playing a role in both tumor killing and early 
elimination of viral infection through humoral (example, antibody and complement binding) and cellular 
mechanisms (Wakimoto et al., 2003). Exogenous factors include cellular stress resulting from chemo- and/or 
radiotherapy and reovirus modulation of interferon signaling (Prestwich et al., 2008). The presence of “infected” 
tumor cells and the release of viral- and tumor associated antigens after tumor cell lysis, induce robust innate and 
adaptive antitumor immune responses (Adair et al., 2013; Gujar and Lee, 2014; Hall et al., 2012). 
Combination therapy can overcome pre-existing immunity to reovirus without affecting metastatic tumor 
regression. Reovirus has been shown to preferentially infect, induce ER stress and kill Ras-activated pancreatic 
cancer cells (Carew et al., 2013). Furthermore, IP admin istration of RV inhibits the peritoneal dissemination of 
pancreatic cancer cells in a syngeneic immunocompetent animal model (Hirano et al., 2009). Intraportal 
administration of reovirus has decreased the number and size of treated tumors in the same model (Himeno et al., 
2005). 
This therapeutic approach faces a major challenge consisting of the immune system’s response to the virus, 
which hinders oncolytic virotherapy. To date, complex dynamics of oncolytic viral tumor infection and the 
consequences of OV-induced immune response are poorly understood (Workenhe et al., 2015; Woller et al., 2014 
and Alvarez-Breckenridge et al., 2015). Denderitic cells and NK cells produce a range of cytokines that promotes 
T helper 1 cell activity and potent cytotoxic T lymphocyte responses that are necessary for clearing virus-infected 
cells (Romagn ani et al., 2005). 
Additionally, humoral immune responses, namely the production of neutralizing antibodies by B cells and 
plasma cells, provide several lines of antiviral defense (Dorner and Radbruch, 2007). Plasma cells derived from 
B1 cells imparts early defense against viral infection by producing polyspecific antibodies. CD4+ T helper cells 
then stimulate naive B cells at later stages, in order to generate memory B cells and long-lived plasma cells that 
produce high amounts of specific neutralizing IgG antibodies. Finally, the complement system, composed of 
soluble factors and cell surface receptors, blocks viral infection by acting on both the innate and adaptive immune 
responses. These mechanisms include, enhancing humoral immunity, regulating antibody effector mechanisms, 
and modulating T cell function (Stoermer and Morrison, 2010).  
The infectious potential of recognized OVs (example, Ad, HSV) becomes limited by high levels of 
neutralizing antibodies (Massari et al., 2002). These circulating antibodies can limit viruses from ever reaching 
the tumor site, especially since some viral particles, including HSV-1- and murine leukemia virus-derived viruses, 
are particularly prone to inactive action by the comple ment system (Ikeda et al., 2000). Poxviruses elicit a strong 
cell mediated immune response and are ultimately cleared from the body by the humoral immune system, 
preventing poxviruses from causing latent or recurrent infection (Chaudhri et al., 2004). 
2.3.2 Tumor environment 
The immune system has often being perceived as a major impediment to successful oncolytic virus therapy by 
facilitating viral clearance (Prestwich et al., 2009 and Bridle et al., 2010). Even though intratumoral viral injections 
offer direct tumor infection, they are of limited use in regions (such as the brain) where the tumor cannot be reached 
directly (Crittenden et al., 2005). Intrinsic barriers within the tumor microenvironment, such as dense intratumoral 
connective tissue and induction of antiviral immunity, can impair these processes. Alteration of the 
microenvironment by administering exogenous enzymes directly to the tumor or by equipping viruses to encode 
recombinant enzymes can facilitate viral spread (Guedan et al., 2010). 
Tumor-infiltrating leukocytes can negatively regulate immune responses within the tumor, which include 
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regulatory T cells (Tregs), myeloid derived suppressor cells, and type 2 macrophages. Their immunosuppressive 
functions can be exerted by secretion of cytokines (e.g., IL-10 and TGF-β), through inhibitory receptors (e.g. 
CTLA-4 and PD-L1) via cell contact, and secretion of amino-acid depleting enzymes (arginase and IDO) in the 
tumor microenvironment. Tumor cells themselves also have mechanisms to suppress antitumor immunity, such as 
the shedding of NKG2D ligands, MICA/B that blocks NK cell and T cell function (Groh et al., 2002) and facilitates 
the expansion of immunosuppressive CD4+ T cells (Groh et al., 2006). 
Oncolytic virotherapy has the potential benefit of altering the tumor microenvironment enough to break 
existing tumor immunotolerance. Failure of the immune system to recognize tumor cells may be due to a paucity 
of stimulated immune cells infiltrating the tumor and/or masking of tumor or antigens. Aberrant cytokine patterns 
in the tumor microenvironment may severely limit an antitumor immune response (Zou, 2005). 
2.3.3 Challenges of combination theraphy 
Although seropositivity for herpes simplex virus is common and could prevent booster inject- ions, preclinical and 
clinical data suggest that pre-existing antiherpes antibody titers do not appreciably impact therapeutic responses, 
which may relate to the intratumoral route of admin isteration. Because local antiviral immunity may limit 
therapeutic efficacy, strategies to limit local immune response have been used to enhance the oncolytic activity of 
herpes simplex virus vectors. For example, cyclophosphamide has been used to block bone marrow-derived 
generation of inflammatory cells prior to administration of herpes simplex virus (Currier et al., 2008; Fulci et al., 
2006).  
Another approach is the use of agents either exogenously administered (eg. cilengitide, bevacizumab) or re 
engineered into the virus (eg. vasculostatin) to inhibit vascular permeability or formation of neovasculature in the 
tumor to limit the extravasation of inflammatory cells into the tumor, and permit enhanced virus production in 
tumor cells (Kaur et al., 2005;  Kurozumi et al., 2008). Introducing genes that are make cancer cells more sensitive 
to standard chemotherapy or for radiation treatments. Drug convertases (“suicide genes”) which can turn an 
inactive prodrug into an active drug which can be introduced to tumor cells to cause cell-specific toxicity. For 
example, the herpesvirus thymidine kinase can phosphorylate and convert nontoxic drug ganciclovir into toxic 
metabolites (Mullen and Tanabe, 2003). 
Serum from individuals who were sero-positive for CVA21 failed to show cross-neutralization to other group 
A coxsackie viruses, that is, A13, A15, or A18. Thus, prime boost strategies utilizing alternate strains of coxsackie 
A virus might be one approach to increase antitumor immunity and therapeutic responses with oncolytic coxsackie 
viruses (Au et al., 2011). However, as far as veterinary medicine is concerned, development of oncolytic 
virotherapy for cancer to heal canine patients is of prime importance. Many of the treatment options used in 
veterinary medicine rese- mble protocols used to treat human cancer patients. In addition, public release of nearly 
99% canine genome sequences provided a window of opportunity to expand the scope of comparative oncology 
(MacTavish et al., 2010). 
The most common immunosuppressant drug used in the context of oncolytic virotherapy is 
cyclophosphamide; a chemotherapeutic alkylating agent that also induces apoptotic cell death. CPA has complex 
immune-modulating effects, affecting humoral and cellular mediators of both the innate and acquired immune 
responses. These immunosuppressive functions have been shown to enhance viral oncolysis and improve 
antitumor efficacy of HSV (Ikeda et al., 2003; Kambara et al., 2005). Some OVs can actually stimulate 
angiogenesis to increase vascular perm eability in tumors (Aghi et al., 2007). 
Thus, anti-angiogenic therapy may thus adversely affect the localization of OVs to the tumor 
microenvironment. Finally, modulation of the host immune response through chemotherapy may conflict with the 
therapeutic function of the oncolytic virus. For instance, low dose CPA may remove immunosuppressive cells 
such as Tregs to improve vaccine induced adaptive antitumor immune responses; however, it also promotes the 
antiviral immune response, leading to early viral clearance (Bartlett et al., 2013). Conversely, high dose CPA may 
enhance viral oncolysis through wide spread immunosuppression of the innate and adaptive antiviral immune 
response, but also completely abrogate the antitumor immune response (Prestwich et al., 2008). 
 
3. CONCLUSION  
Oncolytic virotherapy constitutes an alternative treatment option for a broad spectrum of cancer entities and 
quickly moving toward the forefront of modern medicines. By direct and indirect mechanisms of tumor killing, 
virotherapy provide rationale for investigation of clinical trials using engineered OVs in support of conventionl 
cancer therapy as well as in combination with immune checkpoint inhibitors. In general the tumor selective 
property of oncolytic viruses method is based on the capability of OVs to preferentially infect and lyses cancer 
cells and to initiate specific antitumor immune response. After genetic engineering, The other advantage of 
oncolytic virotherapy is that, OVs selectively replicate in cancer cells leads to tumor cell destruction and oncolysis. 
On top of this, a better understanding of the functional roles of various viral genes has aided the modification of 
oncolytic viruses to alter tumor selectivity, pathogenicity, and immunogenicity, and to optimize the clinical 
potential of these vectors. Concomint to the current encouragement of more study on oncolytic virus enter human 
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clinical trials, more oncolytic therapeutics may become available for use in companion animals in near future. 
Hence, further investigation is needed to give attention on type of cancers and stages of disease, viral dose and 
mode of immune cells enforced. Further research on the optimization of the OV-drug combination strategies for 
both the oncolytic and antitumor immune effects of OVs is requires. On top of this, the clinical impact of oncolytic 
viruses and the potential promise of this approach for the treatment of animal cancers need to be investigated.  
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